Bank of America
INO icon

Bank of America’s Inovio Pharmaceuticals INO Stock Holding History

Bank of America’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,400
Closed -$550K – 8401
2021
Q3 		$550K Sell
6,400
-6,875
-52% -$690K ﹤0.01% 5578
2021
Q2 		$1.48M Sell
13,275
-7,642
-37% -$734K ﹤0.01% 4564
2021
Q1 		$2.33M Buy
+20,917
New +$2.75M ﹤0.01% 4130
2020
Q4 		– Sell
-81,475
Closed -$11.3M – 7206
2020
Q3 		$11.3M Buy
81,475
+73,142
+878% +$15.3M ﹤0.01% 2187
2020
Q2 		$2.69M Buy
+8,333
New +$1.34M ﹤0.01% 3386

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America's INO Position: Q2 2026 in Review

Bank of America sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 32,677 shares — an estimated $56.9K sold.

Bank of America first reported a position in INO in Q2 2013 and held it in 52 quarters. The position peaked at $12.8M in Q3 2020. 102 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Bank of America reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bank of America sold 32,677 Inovio Pharmaceuticals shares in Q2 2026, an estimated $56.9K.
  • Bank of America first reported a position in Inovio Pharmaceuticals in Q2 2013 and held it in 52 quarters.
  • Bank of America's Inovio Pharmaceuticals position peaked at $12.8M in Q3 2020.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.